Low Dose Naltrexone (LDN) is increasingly used by clinicians for management of challenging medical conditions such as chronic pain or autoimmune disorders.
Read More
Naltrexone is classified as an opioid antagonist. Naltrexone blocks opiate drugs from binding to the opioid receptors, which can result in increased endorphin and enkephalin release. This causes a biological response that results in reduced signaling and release of inflammatory substances, nerve cell inflammation and autoimmune mediators. LDN has been studied across a wide variety of autoimmune conditions and cancer diagnosis.
Read More
COVID-19 sparks an inflammatory immune response that is essential to control and eliminate the infection, however, certain immune responses can cause a decrease of gas exchange in the lungs.
Read More
Over the last several years there has been an explosion in research on LDN to treat a variety of autoimmune diseases. PubMed, a literature repository for the US National Library of Medicine, lists 230 published studies from respected academic organizations like Stanford, Harvard, Penn State, Brown University and the Mayo Clinic. LDN is most commonly used to treat Fibromyalgia, Chronic Fatigue, Multiple Sclerosis, Psoriasis, and Autoimmune Thyroid Diseases. Additional research is being conducted on over 100 other health conditions.
Read More